Ástralía - enska - Department of Health (Therapeutic Goods Administration)

alexion pharmaceuticals australasia pty ltd - ravulizumab, quantity: 100 mg/ml - injection, concentrated - excipient ingredients: monobasic sodium phosphate; dibasic sodium phosphate; polysorbate 80; arginine; sucrose; water for injections - ultomiris is indicated:,? for the treatment of patients with paroxysmal nocturnal haemoglobinuria (pnh),? for the treatment of patients with atypical haemolytic uraemic syndrome (ahus),? as an add-on to standard therapy for the treatment of adult patients with generalised myasthenia gravis (gmg) who are anti-acetylcholine receptor (achr) antibody-positive.,? for the treatment of adult patients with neuromyelitis optica spectrum disorder (nmosd) who are anti-aquaporin 4 (aqp4) antibody-positive.,ultomiris is not intended for the acute treatment of a nmosd relapse.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

alexion pharmaceuticals australasia pty ltd - ravulizumab, quantity: 100 mg/ml - injection, intravenous infusion - excipient ingredients: monobasic sodium phosphate; dibasic sodium phosphate; polysorbate 80; arginine; sucrose; water for injections - ultomiris is indicated:,? for the treatment of patients with paroxysmal nocturnal haemoglobinuria (pnh),? for the treatment of patients with atypical haemolytic uraemic syndrome (ahus),? as an add-on to standard therapy for the treatment of adult patients with generalised myasthenia gravis (gmg) who are anti-acetylcholine receptor (achr) antibody-positive.,? for the treatment of adult patients with neuromyelitis optica spectrum disorder (nmosd) who are anti-aquaporin 4 (aqp4) antibody-positive.,ultomiris is not intended for the acute treatment of a nmosd relapse.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

lacorium health international pty ltd - oatmeal colloidal, quantity: 20 mg/g - lotion - excipient ingredients: aluminium magnesium silicate; benzyl alcohol; cetostearyl alcohol; ethylhexylglycerin; glycerol; xanthan gum; white beeswax; phenoxyethanol; simmondsia chinensis; medium chain triglycerides; purified water; glyceryl monostearate; glyceryl stearate citrate; sodium hydroxide

Ísrael - enska - Ministry of Health

alexion pharma israel ltd - asfotase alfa - solution for injection - asfotase alfa 100 mg / 1 ml - asfotase alfa - strensiq is indicated for long-term enzyme replacement therapy in patients with paediatric-onset hypophosphatasia to treat the bone manifestations of the disease.

Ísrael - enska - Ministry of Health

alexion pharma israel ltd - asfotase alfa - solution for injection - asfotase alfa 40 mg / 1 ml - asfotase alfa - strensiq is indicated for long-term enzyme replacement therapy in patients with paediatric-onset hypophosphatasia to treat the bone manifestations of the disease.

Bandaríkin - enska - NLM (National Library of Medicine)

lacorium health usa inc - oatmeal (unii: 8pi54v663y) (oatmeal - unii:8pi54v663y) - skin protectant temporarily protects and relieves minor skin irritation and itching due to: - eczema - dermatitis - rashes

Bandaríkin - enska - NLM (National Library of Medicine)

lacorium health usa inc - oatmeal (unii: 8pi54v663y) (oatmeal - unii:8pi54v663y) - skin protectant temporarily protects and relieves minor skin irritation and itching due to: - eczema - dermatitis - rashes

Bandaríkin - enska - NLM (National Library of Medicine)

lacorium health international pty ltd - tolnaftate (unii: 06kb629tkv) (tolnaftate - unii:06kb629tkv) - antifungal - clinically proven to prevent athlete's foot (tinea pedis) and ringworm (tinea corporis) with daily use - for effective relief of symptoms of athlete's foot, including itching, burning, cracking, scaling and discomfort associated with this condition.

Malasía - enska - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

a. menarini singapore pte. ltd. - magnesium hydroxide; simethicone; sodium polyhydroxyaluminium mono-carbonate hexitol complex -

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

alexion pharmaceuticals australasia pty ltd - asfotase alfa, quantity: 40 mg/ml - injection, solution - excipient ingredients: sodium chloride; dibasic sodium phosphate heptahydrate; water for injections; monobasic sodium phosphate monohydrate - strensiq (asfotase alfa, rch) is indicated as enzyme replacement therapy in patients with paediatric-onset hypophosphatasia.